~~<i id='D5000A77E2'><strike id='D5000A77E2'><tt id='D5000A77E2'><pre id='D5000A77E2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

comprehensive

author：explore 2025-09-28 21:07:01 - browse：66

AP/Richard Drew

Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development.

The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry.

Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Vertex non

explore

hotspot

entertainment

leisure time

knowledge

AdobeChicagopediatrichospitalLurieChildren’shasbeenforcedtotakeitsnetworkofflineinthefaceofa“cyberse

WSS

Congressmen charge Covid hearing ‘could have been an email’

5 shark bites reported on Long Island as officials deploy surveillance drones

SAMSHA loosens regulations on methadone treatment centers

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

5 shark bites reported on Long Island as officials deploy surveillance drones

ARCH Venture Partners is raising $3 billion for a life sciences fund

hotspot

comprehensive

explore

Malaria cases in Florida and Texas: Here’s what you need to know

FDA drug safety: Singulair case shows systemic surveillance flaws

ChatGPT in medicine: STAT answers readers' burning questions

Some dementia cases could be undiagnosed liver disease

In Memoriam: Notable people who died in 2023

Congressmen charge Covid hearing ‘could have been an email’

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Dramatic video released of Russian fighter jets 'harassing' US drones over Syria

23andMe had bad news about my health. I wish a person had delivered it

Time to name cancers by genetics, not organ of origin, expert says

explore

FDA drug safety: Singulair case shows systemic surveillance flaws

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

ARCH Venture Partners is raising $3 billion for a life sciences fund

Following judge's order, DOJ releases slightly less

Pentagon will tighten controls on classified information after Discord leak

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

hotspot

entertainment

leisure time

knowledge